INTRODUCTION: Elagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to uterine fibroids. The pharmacokinetics of elagolix have been well-characterized in phase I studies; however, elagolix population pharmacokinetics have not been previously reported. Therefore, a robust model was developed to describe elagolix population pharmacokinetics and to evaluate factors affecting elagolix pharmacokinetic parameters. METHODS: The data from nine clinical studies (a total of 1624 women) were included in the analysis: five phase I studies in healthy, premenopausal women and four phase III studies in premenopausal women with endometriosis. RESULTS: Elagolix population pharmacokinetics were best described by a two-compartment model with a lag time in absorption. Of the 15 covariates tested for effect on elagolix apparent clearance (CL/F) and/or volume of distribution only one covariate, organic anion transporting polypeptide (OATP) 1B1 genotype status, had a statistically significant, but not clinically meaningful, effect on elagolix CL/F. CONCLUSION: Elagolix pharmacokinetics were not affected by patient demographics and were similar between healthy women and women with endometriosis. Clinical Trial Registration Numbers NCT01403038, NCT01620528, NCT01760954, NCT01931670, NCT02143713.
INTRODUCTION:Elagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to uterine fibroids. The pharmacokinetics of elagolix have been well-characterized in phase I studies; however, elagolix population pharmacokinetics have not been previously reported. Therefore, a robust model was developed to describe elagolix population pharmacokinetics and to evaluate factors affecting elagolix pharmacokinetic parameters. METHODS: The data from nine clinical studies (a total of 1624 women) were included in the analysis: five phase I studies in healthy, premenopausal women and four phase III studies in premenopausal women with endometriosis. RESULTS:Elagolix population pharmacokinetics were best described by a two-compartment model with a lag time in absorption. Of the 15 covariates tested for effect on elagolix apparent clearance (CL/F) and/or volume of distribution only one covariate, organic anion transporting polypeptide (OATP) 1B1 genotype status, had a statistically significant, but not clinically meaningful, effect on elagolix CL/F. CONCLUSION:Elagolix pharmacokinetics were not affected by patient demographics and were similar between healthy women and women with endometriosis. Clinical Trial Registration Numbers NCT01403038, NCT01620528, NCT01760954, NCT01931670, NCT02143713.
Authors: R Scott Struthers; TaKung Chen; Bruce Campbell; Roland Jimenez; Henry Pan; Samuel S C Yen; Haig P Bozigian Journal: J Clin Endocrinol Metab Date: 2006-07-18 Impact factor: 5.958
Authors: R Scott Struthers; Andrew J Nicholls; John Grundy; Takung Chen; Roland Jimenez; Samuel S C Yen; Haig P Bozigian Journal: J Clin Endocrinol Metab Date: 2008-11-25 Impact factor: 5.958
Authors: Bruce Carr; W Paul Dmowski; Chris O'Brien; Ping Jiang; Joshua Burke; Roland Jimenez; Elizabeth Garner; Kristof Chwalisz Journal: Reprod Sci Date: 2014-09-23 Impact factor: 3.060
Authors: Ivan Urits; Leena Adamian; Paulo Miro; Jessica Callan; Parth M Patel; Megha Patel; Amnon A Berger; Hisham Kassem; Alan D Kaye; Omar Viswanath Journal: Psychopharmacol Bull Date: 2020-10-15
Authors: Ahmed Abbas Suleiman; Ahmed Nader; Insa Winzenborg; Denise Beck; Akshanth R Polepally; Juki Ng; Peter Noertersheuser; Nael M Mostafa Journal: CPT Pharmacometrics Syst Pharmacol Date: 2020-10-08
Authors: Insa Winzenborg; Akshanth R Polepally; Ahmed Nader; Nael M Mostafa; Peter Noertersheuser; Juki Ng Journal: CPT Pharmacometrics Syst Pharmacol Date: 2020-07-31
Authors: Mohamad Shebley; Akshanth R Polepally; Ahmed Nader; Juki W Ng; Insa Winzenborg; Cheri E Klein; Peter Noertersheuser; Megan A Gibbs; Nael M Mostafa Journal: Clin Pharmacokinet Date: 2020-03 Impact factor: 6.447